Adverse effects of metamizole on heart, lung, liver, kidney, and stomach in rats

• Published in: BMC pharmacology & toxicology Vol. 25; no. 1; p. 55
• Main Authors: Ciftel, Sedat, Suleyman, Bahadir, Mammadov, Renad, Coskun, Resit, Coban, Taha A, Mokhtare, Behzad, Suleyman, Halis, Cerrah, Serkan, Cicek, Betul, Suleyman, Zeynep
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.08.2024; BioMed Central
• Subjects: Alanine; Alanine transaminase; Analgesics; Animal tissues; Animals; Anti-Inflammatory Agents, Non-Steroidal - toxicity; Aspartate; Aspartate aminotransferase; Blood; Catalase; Catalase - metabolism; Complications and side effects; Coronary artery disease; Creatinine; Damage detection; Dipyrone - toxicity; Enzymes; Glutathione; Glutathione - metabolism; Heart; Heart - drug effects; Heart diseases; Kidney - drug effects; Kidney - metabolism; Kidney - pathology; Kidney diseases; Kidneys; Liver; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver diseases; Lung - drug effects; Lung - metabolism; Lung - pathology; Lung diseases; Lungs; Male; Malondialdehyde - metabolism; Myocardium - metabolism; Myocardium - pathology; Nonsteroidal anti-inflammatory drugs; Oral administration; Pharmaceutical industry; Rats; Stomach; Stomach - drug effects; Stomach - pathology; Superoxide; Superoxide dismutase; Superoxide Dismutase - metabolism; Toxicity; Transaminases; Troponin; Urea; Germany; Turkey; Heart; Stomach; Metamizole; Oxidative damage; Liver; Lung; Kidney
• ISSN: 2050-6511; 2050-6511
• DOI: 10.1186/s40360-024-00780-4

Metamizole is banned in some countries because of its toxicity, although it is widely used in some European countries. In addition, there is limited information on its safety profile, and it is still debated whether it is toxic to the heart, lungs, liver, kidneys, and stomach. Our study investigated the effects of metamizole on the heart, lung, liver, kidney, and stomach tissues of rats. Eighteen rats were divided into three groups, wassix healthy (HG), 500 mg/kg metamizole (MT-500), and 1000 mg/kg metamizole (MT-1000). Metamizole was administered orally twice daily for 14 days. Meanwhile, the HG group received pure water orally. Biochemical, histopathologic, and macroscopic examinations were performed on blood samples and tissues. Malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) in the lung and gastric tissues of MT-500 and MT-1000 groups were almost the same as those of the HG (p > 0.05). However, MDA levels in the heart and liver tissues of MT-500 and MT-1000 groups were higher (p < 0.05) compared to the HG, while tGSH levels and SOD, and CAT activities were lower (p < 0.05). MDA levels of MT-500 and MT-1000 groups in the kidney tissue increased the most (p < 0.001), and tGSH levels and SOD and CAT activities decreased the most (p < 0.001) compared to HG. Metamizole did not cause oxidative damage in the lung and gastric tissue. While metamizole did not change troponin levels, it significantly increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine levels compared to HG. Histopathologically, mild damage was detected in heart tissue, moderate damage in liver tissue, and severe damage in renal tissue. However, no histopathologic damage was found in any groups' lung and gastric tissues. Metamizole should be used under strict control in patients with cardiac and liver diseases and it would be more appropriate not to use it in patients with renal disease.